BE2010C033I2 - - Google Patents

Download PDF

Info

Publication number: BE2010C033I2
Authority: BE; Belgium
Prior art keywords: conjugate; meningococcal serogroup; buffer; aluminium; provides
Prior art date: 2001-06-20

Application number

BE2010C033C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-20

Filing date

2010-09-13

Publication date

2021-07-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9917070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2010C033(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-09-13 Application filed by Novartis Ag filed Critical Novartis Ag

2021-07-19 Publication of BE2010C033I2 publication Critical patent/BE2010C033I2/fr

Links

239000002671 adjuvant Substances 0.000 abstract 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
229940001007 aluminium phosphate Drugs 0.000 abstract 1
229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/04—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from fish or other sea animals
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09F—NATURAL RESINS; FRENCH POLISH; DRYING-OILS; OIL DRYING AGENTS, i.e. SICCATIVES; TURPENTINE
- C09F1/00—Obtaining purification, or chemical modification of natural resins, e.g. oleo-resins
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09G—POLISHING COMPOSITIONS; SKI WAXES
- C09G1/00—Polishing compositions
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Formation And Processing Of Food Products (AREA)

BE2010C033C 2001-06-20 2010-09-13 BE2010C033I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0115176.0A GB0115176D0 (en)	2001-06-20	2001-06-20	Capular polysaccharide solubilisation and combination vaccines
PCT/IB2002/003191 WO2003007985A2 (fr)	2001-06-20	2002-06-20	Solubilisation de polysaccharides capsulaires et vaccins de combinaison

Publications (1)

Publication Number	Publication Date
BE2010C033I2 true BE2010C033I2 (fr)	2021-07-19

Family

ID=9917070

Family Applications (4)

Application Number	Title	Priority Date
BE2010C032C BE2010C032I2 (fr)	2001-06-20	2010-09-13
BE2010C031C BE2010C031I2 (fr)	2001-06-20	2010-09-13
BE2010C033C BE2010C033I2 (fr)	2001-06-20	2010-09-13
BE2011C001C BE2011C001I2 (fr)	2001-06-20	2011-01-13

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
BE2010C032C BE2010C032I2 (fr)	2001-06-20	2010-09-13
BE2010C031C BE2010C031I2 (fr)	2001-06-20	2010-09-13

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BE2011C001C BE2011C001I2 (fr)	2001-06-20	2011-01-13

Country Status (23)

Country	Link
US (9)	US8753651B2 (fr)
EP (10)	EP2189165B1 (fr)
JP (4)	JP5075317B2 (fr)
CN (4)	CN100482273C (fr)
AT (3)	ATE474594T1 (fr)
AU (3)	AU2002321716B2 (fr)
BE (4)	BE2010C032I2 (fr)
BR (2)	BRPI0210590B8 (fr)
CA (3)	CA2641585C (fr)
CY (6)	CY1110820T1 (fr)
DE (6)	DE122010000042I1 (fr)
DK (6)	DK1741442T3 (fr)
ES (9)	ES2603275T3 (fr)
FR (4)	FR10C0042I1 (fr)
GB (1)	GB0115176D0 (fr)
LU (4)	LU91733I2 (fr)
MX (1)	MXPA03011462A (fr)
NL (3)	NL300458I2 (fr)
NZ (2)	NZ544332A (fr)
PT (6)	PT1741442E (fr)
RU (2)	RU2381814C2 (fr)
TR (2)	TR201808055T4 (fr)
WO (1)	WO2003007985A2 (fr)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9928196D0 (en)	1999-11-29	2000-01-26	Chiron Spa	Combinations of B, C and other antigens
EP2957300B1 (fr)	2001-01-23	2021-07-14	Sanofi Pasteur Inc.	Vaccin conjugué de protéine et de polysaccharide pour méningococcie polyvalente
GB0115176D0 (en) *	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) *	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003080678A1 (fr) *	2002-03-26	2003-10-02	Chiron Srl	Saccharides modifies presentant une stabilite amelioree dans l'eau
DE60328481D1 (de)	2002-05-14	2009-09-03	Novartis Vaccines & Diagnostic	Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) *	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
DE20321889U1 (de) *	2002-08-02	2012-03-12	Glaxosmithkline Biologicals S.A.	Impfstoffzusammensetzung
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
DK2353608T3 (da) *	2002-10-11	2020-02-10	Novartis Vaccines And Diagnostics S R L	Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
DK2279746T3 (da)	2002-11-15	2013-11-25	Novartis Vaccines & Diagnostic	Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
DK1587537T3 (da) *	2003-01-30	2012-07-16	Novartis Ag	Injicerbare vacciner mod multiple meningococ-serogrupper
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
BRPI0411815A (pt) *	2003-06-23	2006-08-08	Baxter Int	vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
GB0323103D0 (en) *	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
SI1670506T1 (sl) *	2003-10-02	2013-03-29	Novartis Ag	Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0406013D0 (en) *	2004-03-17	2004-04-21	Chiron Srl	Analysis of saccharide vaccines without interference
GB0408977D0 (en)	2004-04-22	2004-05-26	Chiron Srl	Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en)	2004-04-22	2004-05-26	Chiron Srl	Meningococcal fermentation for preparing conjugate vaccines
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
SI1740217T1 (sl)	2004-04-30	2011-10-28	Novartis Ag	Konjugirano meningokokno cepljenje
GB0410866D0 (en)	2004-05-14	2004-06-16	Chiron Srl	Haemophilius influenzae
GB0411387D0 (en) *	2004-05-21	2004-06-23	Chiron Srl	Analysis of saccharide length
GB0413868D0 (en)	2004-06-21	2004-07-21	Chiron Srl	Dimensional anlaysis of saccharide conjugates
AU2005279821A1 (en) *	2004-08-30	2006-03-09	Sanofi Pasteur, Inc.	Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
CA2580693A1 (fr) *	2004-09-21	2006-03-30	Sanofi Pasteur, Inc.	Conjugues polysaccharide/proteine menogococciques multivalents derivatises et vaccin
GB0424092D0 (en)	2004-10-29	2004-12-01	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
GB0502096D0 (en) *	2005-02-01	2005-03-09	Chiron Srl	Purification of streptococcal capsular polysaccharide
GB0502095D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
SI1858920T1 (sl)	2005-02-18	2016-07-29	Glaxosmithkline Biologicals S.A.	Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
NZ580974A (en)	2005-02-18	2011-05-27	Novartis Vaccines & Diagnostic	Immunogens from uropathogenic escherichia coli
GB0505518D0 (en) *	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
KR102378962B1 (ko)	2005-04-08	2022-03-28	와이어쓰 엘엘씨	다가 폐렴구균 다당류-단백질 접합체 조성물
EP1871411A4 (fr)	2005-04-18	2010-07-21	Novartis Vaccines & Diagnostic	Procede pour exprimer un antigene de surface de virus de l'hepatite b afin de preparer un vaccin
GB0513071D0 (en) *	2005-06-27	2005-08-03	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0513069D0 (en) *	2005-06-27	2005-08-03	Glaxosmithkline Biolog Sa	Immunogenic composition
US9486515B2 (en) *	2005-06-27	2016-11-08	Glaxosmithkline Biologicals S.A.	Immunogenic composition
CA2621023C (fr)	2005-09-01	2019-07-02	Novartis Vaccines And Diagnostics Gmbh & Co. Kg	Vaccination multiple comprenant des meningocoques du serogroupe c
CA2621578C (fr) *	2005-09-05	2014-07-22	Glaxosmithkline Biologicals S.A.	Essai d'activite bactericide serique pour des antiserums specifiques de n. meningitidis
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
CA2644724C (fr)	2006-03-17	2016-05-24	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Procede de preparation de conjugues immunogeniques multivalents complexes
US10828361B2 (en) *	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
AU2007229449A1 (en)	2006-03-22	2007-10-04	Novartis Ag	Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en)	2006-03-22	2006-05-03	Chiron Srl	Separation of conjugated and unconjugated components
TW200806315A (en) *	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CN101081296B (zh) *	2006-05-29	2010-08-04	北京民海生物科技有限公司	一种b型流感嗜血杆菌荚膜多糖制备方法及其联合疫苗
US7491517B2 (en)	2006-07-19	2009-02-17	Jeeri R Reddy	Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
RU2322503C1 (ru) *	2006-07-21	2008-04-20	Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации	Способ получения высокоспецифичной гетерологичной антирабической сыворотки
EP2586790A3 (fr)	2006-08-16	2013-08-14	Novartis AG	Immunogènes d'Escherischia coli pathogènes des voies urinaires
CN102648979B (zh) *	2006-10-10	2014-05-14	惠氏公司	肺炎链球菌3型多糖的纯化
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700136D0 (en)	2007-01-04	2007-02-14	Glaxosmithkline Biolog Sa	Process for manufacturing vaccines
GB0700562D0 (en)	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
PL2436700T3 (pl) *	2007-03-23	2018-12-31	Wyeth Llc	Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
US8398985B2 (en) *	2007-04-23	2013-03-19	Serum Institute Of India Ltd.	Antigenic polysaccharides and process for their preparation
ES2555786T3 (es)	2007-06-04	2016-01-08	Glaxosmithkline Biologicals Sa	Formulación de vacunas contra la meningitis
GB0713880D0 (en)	2007-07-17	2007-08-29	Novartis Ag	Conjugate purification
ES2534671T3 (es) *	2007-09-11	2015-04-27	University Of Guelph	Inmunógenos polisacáridos de la Clostridium difficile
BRPI0818545A2 (pt)	2007-10-19	2017-07-04	Novartis Ag	formulações de vacinais meningocócicas
WO2009104097A2 (fr)	2008-02-21	2009-08-27	Novartis Ag	Polypeptides fhbp à méningocoques
CN101724085B (zh) *	2008-10-22	2011-09-21	上海生物制品研究所	一种荚膜多糖纯化方法
US11065323B2 (en)	2008-10-27	2021-07-20	Glaxosmithkline Biologicals Sa	Purification method
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
GB0822633D0 (en) *	2008-12-11	2009-01-21	Novartis Ag	Formulation
EP2367568A2 (fr)	2008-12-17	2011-09-28	Novartis AG	Vaccins méningococciques comprenant un récepteur de l'hémoglobine
CN102596240B (zh)	2009-08-27	2015-02-04	诺华股份有限公司	包括脑膜炎球菌fHBP序列的杂交多肽
ES2812523T3 (es)	2009-09-30	2021-03-17	Glaxosmithkline Biologicals Sa	Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
US20130022633A1 (en)	2009-10-27	2013-01-24	University Of Florence	MENINGOCOCCAL fHBP POLYPEPTIDES
MX345967B (es)	2009-10-30	2017-02-28	Novartis Ag	Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
AU2011288203A1 (en)	2010-03-18	2012-08-23	Novartis Ag	Adjuvanted vaccines for serogroup B meningococcus
PL3831406T3 (pl)	2010-08-23	2024-09-09	Wyeth Llc	Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
US9057716B2 (en)	2010-09-04	2015-06-16	Novartis Ag	Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
RU2546873C2 (ru)	2010-09-10	2015-04-10	УАЙТ ЭлЭлСи	Нелипидизированные варианты антигенов neisseria meningitidis orf2086
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
WO2012085668A2 (fr)	2010-12-24	2012-06-28	Novartis Ag	Composés
KR20140026392A (ko)	2011-03-02	2014-03-05	노파르티스 아게	저용량의 항원 및/또는 보조제를 갖는 조합 백신
EP2729178A1 (fr)	2011-07-08	2014-05-14	Novartis AG	Procédé de ligature de la tyrosine
CU20110202A7 (es)	2011-11-02	2013-12-27	Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas	Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes
US9493517B2 (en) *	2011-11-07	2016-11-15	Glaxosmithkline Biologicals Sa	Conjugates comprising an antigen and a carrier molecule
HUE040914T4 (hu) *	2012-01-30	2019-05-28	Serum Institute Of India Pvt Ltd	Immunogén készítmény
CN104159603A (zh)	2012-03-08	2014-11-19	诺华股份有限公司	带有tlr4激动剂的联合疫苗
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en)	2012-03-09	2018-09-21	Pfizer	Neisseria meningitidis compositions and methods thereof
EP2852414B9 (fr)	2012-05-22	2020-12-09	GlaxoSmithKline Biologicals SA	Conjugué de sérogroupe x de méningocoque
CN104487086B (zh) *	2012-07-07	2019-08-30	巴拉特生物技术国际有限公司	无动物源的不含酒精的疫苗组合物及其制备方法
CN103623404B (zh) *	2012-08-28	2016-08-03	天士力制药集团股份有限公司	一种b型流感嗜血杆菌多糖结合疫苗的制备方法
BR112015005056A2 (pt)	2012-09-06	2017-11-21	Novartis Ag	vacinas de combinação com sorogrupo b meningococcus e d/t/p
EP2922569B1 (fr)	2012-11-21	2018-01-03	Serum Institute of India Private Limited	Production de hauts rendements de polysaccharides bactériens
BR112015014250A2 (pt)	2012-12-18	2017-07-11	Glaxosmithkline Biologicals Sa	método para imunizar um bebê, vacina de combinação e, kit
US9802987B2 (en)	2013-03-08	2017-10-31	Pfizer Inc.	Immunogenic fusion polypeptides
KR20160040556A (ko)	2013-07-11	2016-04-14	노파르티스 아게	미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
CN105339388B (zh)	2013-07-12	2021-06-15	Emd密理博公司	确定利用活性炭从包含靶蛋白的样品去除病毒的方法
EP4098276A1 (fr)	2013-09-08	2022-12-07	Pfizer Inc.	Compositions utilisables contre neisseria meningitidis et procédés associés
AU2015222121B2 (en)	2014-02-28	2018-01-18	Glaxosmithkline Biologicals Sa	Modified meningococcal fHbp polypeptides
ES2865485T3 (es)	2014-05-24	2021-10-15	Biological E Ltd	Nueva vacuna de conjugado meningocócico semisintético
CN104548090B (zh) *	2015-01-27	2016-11-30	中国科学院过程工程研究所	一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
US10888611B2 (en)	2015-02-19	2021-01-12	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
CN105037579A (zh) *	2015-08-31	2015-11-11	成都欧林生物科技股份有限公司	A群脑膜炎球菌细菌荚膜粗多糖的制备工艺
WO2017175082A1 (fr)	2016-04-05	2017-10-12	Gsk Vaccines S.R.L.	Compositions immunogènes
AU2017321863B2 (en)	2016-09-02	2024-07-11	Sanofi Vaccines US Inc.	Neisseria meningitidis vaccine
CA3035320A1 (fr)	2016-09-02	2018-03-08	Glaxosmithkline Biologicals Sa	Vaccins contre neisseria gonorrhoeae
DK3562503T3 (da) *	2016-12-30	2025-05-26	Vaxcyte Inc	Polypeptid-antigen-konjugater med ikke-naturlige aminosyrer
US11951165B2 (en)	2016-12-30	2024-04-09	Vaxcyte, Inc.	Conjugated vaccine carrier proteins
PE20191107A1 (es)	2017-01-31	2019-08-26	Pfizer	Composiciones de neisseria meningitidis y metodos respectivos
WO2018144799A1 (fr)	2017-02-03	2018-08-09	SCHADECK, Eva, Barbara	Compositions de conjugué saccharide d'haemophilus influenzae-excipient et leurs utilisations
WO2019050818A1 (fr) *	2017-09-07	2019-03-14	Merck Sharp & Dohme Corp.	Procédés de formulation de polysaccharides pneumococciques pour conjugaison à une protéine porteuse
US11400162B2 (en)	2017-02-24	2022-08-02	Merck Sharp & Dohme Llc	Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
EP3585427A4 (fr) *	2017-02-24	2020-12-30	Merck Sharp & Dohme Corp.	Procédés d'amélioration de la filtrabilité de réactions de polysaccharide conjugué à une protéine
CA3062399A1 (fr) *	2017-05-05	2018-11-08	Serum Institute Of India Private Limited	Procede d'elimination d'impuretes de preparations a base de polysaccharide capsulaire bacterien
RU2019140392A (ru) *	2017-05-17	2021-06-17	Мсд Веллком Траст Хиллеман Лабораторис Пвт. Лтд.	Очистка бактериальных полисахаридов
WO2019175900A1 (fr) *	2018-03-16	2019-09-19	Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd.	Purification de polysaccharides de neisseria meningitidis
WO2020182635A1 (fr) *	2019-03-08	2020-09-17	Glaxosmithkline Biologicals Sa	Dérivés carbocycliques et leurs dérivés conjugués, et leur utilisation dans des vaccins
JP2022532142A (ja)	2019-05-10	2022-07-13	グラクソスミスクラインバイオロジカルズソシエテアノニム	コンジュゲートの製造
WO2021059181A1 (fr)	2019-09-27	2021-04-01	Pfizer Inc.	Compositions de neisseria meningitidis et méthodes associées
WO2021099982A1 (fr)	2019-11-22	2021-05-27	Glaxosmithkline Biologicals Sa	Dosage et administration d'un vaccin à base de glycoconjugué de saccharide bactérien
GB202013262D0 (en)	2020-08-25	2020-10-07	Glaxosmithkline Biologicals Sa	Vaccine Composition
CN115721709A (zh) *	2021-08-27	2023-03-03	康希诺生物股份公司	一种肺炎球菌结合疫苗制备方法
GB202115151D0 (en)	2021-10-21	2021-12-08	Glaxosmithkline Biologicals Sa	Methods
GB202208089D0 (en) *	2022-06-01	2022-07-13	Glaxosmithkline Biologicals Sa	Immunogenic composition
GB202208093D0 (en)	2022-06-01	2022-07-13	Glaxosmithkline Biologicals Sa	Immunogenic composition

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB207117A (en)	1923-04-05	1923-11-22	Fernand Prosper Constant Lebru	Improvements in otter boards
US4057685A (en)	1972-02-02	1977-11-08	Abbott Laboratories	Chemically modified endotoxin immunizing agent
US4123520A (en) *	1977-08-01	1978-10-31	Merck & Co., Inc.	Method for preparing high molecular weight meningococcal Group C vaccine
US4134214A (en)	1977-08-05	1979-01-16	Merck & Co., Inc.	Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
DE2748132A1 (de)	1977-10-27	1979-05-03	Behringwerke Ag	Stabilisator fuer polysaccharid
US4220717A (en)	1977-12-22	1980-09-02	American Cyanamid Company	Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4242501A (en) *	1979-08-08	1980-12-30	American Cyanamid Company	Purification of pneumococcal capsular polysaccharides
US4351762A (en)	1981-03-10	1982-09-28	Bioresearch, Inc.	Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en)	1981-05-27	1982-10-26	Canadian Patents & Development Ltd.	Immunogenic polysaccharide-protein conjugates
BE889979A (fr)	1981-08-14	1982-02-15	Smith Kline Rit	Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US4902506A (en)	1983-07-05	1990-02-20	The University Of Rochester	Immunogenic conjugates
US4673574A (en)	1981-08-31	1987-06-16	Anderson Porter W	Immunogenic conjugates
US4451446A (en) *	1982-03-04	1984-05-29	Smithkline-Rit	Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
US4496538A (en)	1982-07-06	1985-01-29	Connaught Laboratories, Inc.	Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
JPS59176214A (ja) *	1982-11-23	1984-10-05	ザ・ウエルカム・フアウンデ−シヨン・リミテツド	抗原性組成物
EP0109688A3 (fr)	1982-11-23	1986-12-03	The Wellcome Foundation Limited	Complexes, procédés pour leur obtention et formulations contenant de tels complexes
US4459286A (en)	1983-01-31	1984-07-10	Merck & Co., Inc.	Coupled H. influenzae type B vaccine
US4663160A (en)	1983-03-14	1987-05-05	Miles Laboratories, Inc.	Vaccines for gram-negative bacteria
US4762713A (en)	1983-07-05	1988-08-09	The University Of Rochester	Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4761283A (en)	1983-07-05	1988-08-02	The University Of Rochester	Immunogenic conjugates
JPH0720878B2 (ja) *	1983-11-21	1995-03-08	ザウエルカムフアウンデ−シヨンリミテツド	改善された複合体、それらの製造法および該複合体を含有する製剤
US4695624A (en)	1984-05-10	1987-09-22	Merck & Co., Inc.	Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en)	1984-05-10	1989-11-21	Merck & Co., Inc.	Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en)	1984-07-09	1989-02-28	Praxis Biologics, Inc.	Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it)	1985-07-05	1987-12-23	Sclavo Spa	Coniugati glicoproteici ad attivita' immunogenica trivalente
US4814276A (en)	1986-04-25	1989-03-21	Becton, Dickinson And Company	Selective medium for growth of neisseria
US4877613A (en)	1987-08-05	1989-10-31	Biotech Connections, Inc.	Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli
US4761713A (en) *	1987-11-06	1988-08-02	North American Philips Corp.	Glycol based mid-volt capacitor
GB8815795D0 (en)	1988-07-02	1988-08-10	Bkl Extrusions Ltd	Glazing bead
NL8802046A (nl)	1988-08-18	1990-03-16	Gen Electric	Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de)	1988-12-07	1990-06-13	Behringwerke Ag	Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
WO1990006696A2 (fr)	1988-12-19	1990-06-28	Praxis Biologics, Inc.	Vaccin meningocoque de la proteine de la membrane externe de la classe 1
EP0378881B1 (fr)	1989-01-17	1993-06-09	ENIRICERCHE S.p.A.	Peptides synthétiques et leur utilisation comme support universel pour la préparation de conjugués immunogènes convenant au développement de vaccins synthétiques
US4963534A (en)	1989-05-19	1990-10-16	Merck & Co., Inc.	Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
JPH0832638B2 (ja)	1989-05-25	1996-03-29	カイロンコーポレイション	サブミクロン油滴乳剤を含んで成るアジュバント製剤
FI920131A0 (fi)	1989-07-14	1992-01-13	Praxis Biolog Inc	Cytokin- och hormonbaerare foer konjugatvaccin.
IT1237764B (it)	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
WO1991008772A1 (fr) *	1989-12-14	1991-06-27	National Research Council Of Canada	Vaccin conjugue ameliore a base de polysaccharide de meningocoque
SU1750689A1 (ru) *	1990-05-17	1992-07-30	Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова	Способ получени полисахаридно-белковой вакцины против NeISSeRIa меNINGIтIDIS серогруппы В
DE69113564T2 (de)	1990-08-13	1996-05-30	American Cyanamid Co	Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5256294A (en) *	1990-09-17	1993-10-26	Genentech, Inc.	Tangential flow filtration process and apparatus
US5153312A (en)	1990-09-28	1992-10-06	American Cyanamid Company	Oligosaccharide conjugate vaccines
CA2059692C (fr) *	1991-01-28	2004-11-16	Peter J. Kniskern	Vaccin conjugue de polysaccharide contre les pneumocoques
CA2059693C (fr) *	1991-01-28	2003-08-19	Peter J. Kniskern	Antigenes polysaccharides de streptococcus pneumoniae
CA2101648C (fr)	1991-03-12	2003-09-09	Rachel Schneerson	Conjugues polysaccharide-proteine
US5314811A (en)	1992-07-13	1994-05-24	Merck & Co., Inc.	Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
HU9400426D0 (en) *	1991-08-16	1994-05-30	Merck & Co Inc	Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
FR2682388B1 (fr)	1991-10-10	1995-06-09	Pasteur Merieux Serums Vacc	Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
AU3630093A (en)	1992-03-02	1993-10-05	Biocine S.P.A.	Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it)	1992-03-06	1996-07-22		Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
JP3626996B2 (ja)	1992-05-23	2005-03-09	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
NZ253137A (en)	1992-06-25	1996-08-27	Smithkline Beecham Biolog	Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
IL102687A (en)	1992-07-30	1997-06-10	Yeda Res & Dev	Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
EP0689454B2 (fr)	1993-03-23	2005-02-23	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
DE69433341T2 (de)	1993-09-22	2004-04-15	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
ATE229978T1 (de)	1994-07-01	2003-01-15	Chiron Corp	Helicobacter proteine und impstoffe
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
DE69535905D1 (de)	1994-07-15	2009-02-26	Coley Pharm Group Inc	Immunomodulatorische Oligonukleotide
GB9422096D0 (en) *	1994-11-02	1994-12-21	Biocine Spa	Combined meningitis vaccine
US6696065B1 (en) *	1995-05-04	2004-02-24	Aventis Pastuer Limited	Acellular pertussis vaccines and methods of preparation thereof
US5811102A (en)	1995-06-07	1998-09-22	National Research Council Of Canada	Modified meningococcal polysaccharide conjugate vaccines
DE69615362T3 (de)	1995-06-07	2006-07-20	Smithkline Beecham Biologicals S.A.	Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein
US20030157129A1 (en)	1995-06-23	2003-08-21	Smithkline Beecham Biologicals S.A.	Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
IL122588A (en)	1995-06-23	2001-12-23	Smithkline Beecham Biolog	A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
US20020054884A1 (en)	1995-06-23	2002-05-09	Smithkline Beecham Biologicals, Sa	Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
GB9513261D0 (en)	1995-06-29	1995-09-06	Smithkline Beecham Biolog	Vaccines
DK0909323T3 (da)	1996-01-04	2007-05-21	Novartis Vaccines & Diagnostic	Helicobacter pylori-bakterioferritin
JP2001508758A (ja)	1996-02-01	2001-07-03	ノース・アメリカン・バクシーン・インコーポレイテッド	グループｂナイセリア・メニンギチジス外膜（ｍｂ３）タンパク質の酵母からの発現およびワクチン
DK0897427T3 (da) †	1996-02-14	2005-02-14	Merck & Co Inc	Fremgangsmåde til fældning af polysaccharid
DE19630390A1 (de)	1996-07-26	1998-01-29	Chiron Behring Gmbh & Co	Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
JP4162267B2 (ja)	1996-08-27	2008-10-08	カイロンコーポレイション	Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
EP0930893B1 (fr)	1996-10-11	2005-04-13	The Regents of The University of California	Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US6248334B1 (en)	1997-01-08	2001-06-19	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
ATE451124T1 (de)	1997-01-21	2009-12-15	Sanofi Pasteur	Polysaccharid-peptid-konjugate
JP2001527388A (ja)	1997-01-24	2001-12-25	シュバイツゼールム− ウントインフインスティテュトベルン	多糖類の新規単離方法
AU738513B2 (en)	1997-02-28	2001-09-20	University Of Iowa Research Foundation, The	Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en)	1997-03-24	2001-10-09	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6403306B1 (en)	1997-04-09	2002-06-11	Emory University	Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
EP0977588B1 (fr)	1997-04-24	2004-10-06	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Couplage de proteines non modifiees a des polysaccharides derives d'haloacyle ou de dihaloacyle pour la preparation de vaccins renfermant des proteines-polysaccharides
WO1998052581A1 (fr)	1997-05-20	1998-11-26	Ottawa Civic Hospital Loeb Research Institute	Vecteurs et procedes destines a l'immunisation et a des protocoles therapeutiques
PT1849860E (pt)	1997-05-28	2011-02-23	Novartis Vaccines & Diagnostic	Processo de preparação de um factor imunogénico de corynebacterium diphtheriae utilizando um meio de cultura com extracto de levedura como fonte de aminoácidos e sem complexos proteicos de origem animal
JP4101888B2 (ja)	1997-06-06	2008-06-18	ダイナバックステクノロジーズコーポレイション	免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
GB9712347D0 (en)	1997-06-14	1997-08-13	Smithkline Beecham Biolog	Vaccine
GB9713156D0 (en)	1997-06-20	1997-08-27	Microbiological Res Authority	Vaccines
EP0994723A1 (fr) *	1997-06-24	2000-04-26	Chiron Corporation	Procedes permettant d'immuniser des adultes grace a des compositions de vaccins anti-meningococcique
PT1630168E (pt) *	1997-08-27	2011-07-20	Novartis Vaccines & Diagnostic	Compostos miméticos moleculares de péptidos de meningococos do serogrupo b
CA2302554C (fr)	1997-09-05	2007-04-10	Smithkline Beecham Biologicals S.A.	Emulsions huile-dans-l'eau contenant des saponines
US5965714A (en)	1997-10-02	1999-10-12	Connaught Laboratories, Inc.	Method for the covalent attachment of polysaccharides to protein molecules
EP1029052B1 (fr)	1997-11-06	2010-08-04	Novartis Vaccines and Diagnostics S.r.l.	Antigenes de neisseria
ES2278420T3 (es)	1997-11-21	2007-08-01	Serono Genetics Institute S.A.	Secuencia genomica y polipeptidos de chlamydia pneumoniae, fragmentos de los mismos y uso de los mismos, en particular para diagnostico, prevencion y tratamiento de infeccion.
GB9725084D0 (en)	1997-11-28	1998-01-28	Medeva Europ Ltd	Vaccine compositions
CN1280619A (zh)	1997-11-28	2001-01-17	根瑟特公司	沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
CA2316975C (fr)	1997-12-23	2009-03-24	North American Vaccine, Inc.	Procedures permettant d'extraire et d'isoler des polysaccharides capsulaires bacteriens destines a etre utilises seuls, en tant que vaccins ou, lies a des proteines, en tant que vaccins conjugues
AU1979599A (en)	1998-01-14	1999-08-02	Chiron S.P.A.	(neisseria meningitidis) antigens
US7018637B2 (en) *	1998-02-23	2006-03-28	Aventis Pasteur, Inc	Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en)	1998-03-05	2001-10-16	The Medical College Of Ohio	IL-12 enhancement of immune responses to T-independent antigens
GB9806456D0 (en) *	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition
HUP0101619A3 (en)	1998-04-09	2003-11-28	Smithkline Beecham Biolog	Adjuvant compositions
CN100379757C (zh)	1998-05-01	2008-04-09	希龙公司	脑膜炎奈瑟球菌抗原和组合物
ES2278446T3 (es)	1998-05-29	2007-08-01	Novartis Vaccines And Diagnostics, Inc.	Vacunas combinadas b/c contra la meningitis.
GB9817052D0 (en)	1998-08-05	1998-09-30	Smithkline Beecham Biolog	Vaccine
NZ509986A (en)	1998-08-19	2003-10-31	Baxter Healthcare S	Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
US6128656A (en) *	1998-09-10	2000-10-03	Cisco Technology, Inc.	System for updating selected part of configuration information stored in a memory of a network element depending on status of received state variable
JP2004511201A (ja)	1998-10-09	2004-04-15	カイロン　コーポレイション	ナイセリアゲノム配列およびそれらの使用方法
DE122007000087I1 (de)	1998-10-16	2008-03-27	Glaxosmithkline Biolog Sa	Adjuvanzsysteme und impfstoffe
AU1722300A (en)	1998-11-12	2000-05-29	Regents Of The University Of California, The	Chlamydia pneumoniae genome sequence
GB9828000D0 (en)	1998-12-18	1999-02-10	Chiron Spa	Antigens
US6146902A (en) *	1998-12-29	2000-11-14	Aventis Pasteur, Inc.	Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
KR100642044B1 (ko)	1999-03-19	2006-11-10	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신
FR2791895B1 (fr)	1999-03-23	2001-06-15	Pasteur Merieux Serums Vacc	Utilisation de trehalose pour stabiliser un vaccin liquide
EP1165796A2 (fr)	1999-04-09	2002-01-02	Techlab, Inc.	Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
CN1227030C (zh)	1999-04-19	2005-11-16	史密丝克莱恩比彻姆生物有限公司	包含皂甙和免疫刺激寡核苷酸的佐剂组合物
BR0010721A (pt)	1999-05-19	2002-06-11	Chiron Spa	Composições de neisserias combinadas
GB9918319D0 (en) *	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
US6531131B1 (en)	1999-08-10	2003-03-11	The United States Of America As Represented By The Department Of Health And Human Services	Conjugate vaccine for Neisseria meningitidis
BR0014285A (pt)	1999-09-24	2002-05-21	Smithkline Beecham Biolog	Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PL355163A1 (en)	1999-09-24	2004-04-05	Smithkline Beecham Biologicals S.A.	Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
GB9925559D0 (en)	1999-10-28	1999-12-29	Smithkline Beecham Biolog	Novel method
ES2307553T3 (es)	1999-12-02	2008-12-01	Novartis Vaccines And Diagnostics, Inc.	Composiciones y procedimientos para estabilizar moleculas biologicas tras liofilizacion.
CA2871789C (fr)	2000-01-17	2017-04-04	Novartis Vaccines And Diagnostics S.R.L.	Vaccin a base de vesicule de membrane externe (omv) comprenant des proteines de membrane externe du serogroupe b de n. meningitis
ES2281409T3 (es)	2000-02-28	2007-10-01	Novartis Vaccines And Diagnostics S.R.L.	Expresion heterologa de proteinas de neisseria.
US6800455B2 (en)	2000-03-31	2004-10-05	Scios Inc.	Secreted factors
OA12302A (en)	2000-06-29	2003-10-24	Glaxosmithkline Biolog Sa	Multivalent vaccine composition.
GB0108364D0 (en) *	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
ATE440861T1 (de)	2000-07-03	2009-09-15	Novartis Vaccines & Diagnostic	Immunisierung gegen chlamydia pneumoniae
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
JP2004509914A (ja) *	2000-09-28	2004-04-02	カイロン　コーポレイション	微粒子組成物およびその製造方法
US7939087B2 (en)	2000-10-27	2011-05-10	Novartis Vaccines And Diagnostics, Inc.	Nucleic acids and proteins from Streptococcus groups A & B
EP2957300B1 (fr) *	2001-01-23	2021-07-14	Sanofi Pasteur Inc.	Vaccin conjugué de protéine et de polysaccharide pour méningococcie polyvalente
WO2002080648A2 (fr) *	2001-04-05	2002-10-17	Chiron Corporation	Augmentation de l'immunite des muqueuses a la suite d'un amorçage parenteral
GB0115176D0 (en) *	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
CA2462646C (fr)	2001-10-03	2013-02-12	Chiron Corporation	Compositions de meningocoque assorties d'un adjuvant
WO2003080678A1 (fr)	2002-03-26	2003-10-02	Chiron Srl	Saccharides modifies presentant une stabilite amelioree dans l'eau
GB0302218D0 (en)	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
MXPA04011248A (es)	2002-05-14	2005-02-17	Chiron Srl	Vacunas mucosales en combinacion para la meningitis bacteriana.
GB0220198D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Modified saccharides,conjugates thereof and their manufacture
DK2353608T3 (da)	2002-10-11	2020-02-10	Novartis Vaccines And Diagnostics S R L	Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
DK1587537T3 (da)	2003-01-30	2012-07-16	Novartis Ag	Injicerbare vacciner mod multiple meningococ-serogrupper
GB0409745D0 (en) *	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
US10828361B2 (en)	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
AU2007229449A1 (en)	2006-03-22	2007-10-04	Novartis Ag	Regimens for immunisation with meningococcal conjugates
GB0822633D0 (en) *	2008-12-11	2009-01-21	Novartis Ag	Formulation
GB2495341B (en) *	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products

2001
- 2001-06-20 GB GBGB0115176.0A patent/GB0115176D0/en not_active Ceased
2002
- 2002-06-20 CA CA2641585A patent/CA2641585C/fr not_active Expired - Lifetime
- 2002-06-20 NZ NZ544332A patent/NZ544332A/en not_active IP Right Cessation
- 2002-06-20 CN CNB028124448A patent/CN100482273C/zh not_active Expired - Lifetime
- 2002-06-20 JP JP2003513590A patent/JP5075317B2/ja not_active Expired - Lifetime
- 2002-06-20 AT AT06075175T patent/ATE474594T1/de active
- 2002-06-20 CA CA2450203A patent/CA2450203C/fr not_active Expired - Lifetime
- 2002-06-20 EP EP09075006.8A patent/EP2189165B1/fr not_active Expired - Lifetime
- 2002-06-20 RU RU2004101284/13A patent/RU2381814C2/ru not_active Application Discontinuation
- 2002-06-20 ES ES09075005.0T patent/ES2603275T3/es not_active Expired - Lifetime
- 2002-06-20 EP EP09075010.0A patent/EP2229954B1/fr not_active Expired - Lifetime
- 2002-06-20 ES ES10179797.5T patent/ES2662015T3/es not_active Expired - Lifetime
- 2002-06-20 EP EP09075009.2A patent/EP2216044B1/fr not_active Expired - Lifetime
- 2002-06-20 PT PT06075175T patent/PT1741442E/pt unknown
- 2002-06-20 US US10/481,457 patent/US8753651B2/en not_active Expired - Lifetime
- 2002-06-20 TR TR2018/08055T patent/TR201808055T4/tr unknown
- 2002-06-20 CN CN200910128140.6A patent/CN101524534B/zh not_active Expired - Lifetime
- 2002-06-20 DE DE122010000042C patent/DE122010000042I1/de active Pending
- 2002-06-20 EP EP09075005.0A patent/EP2184071B1/fr not_active Expired - Lifetime
- 2002-06-20 WO PCT/IB2002/003191 patent/WO2003007985A2/fr not_active Ceased
- 2002-06-20 PT PT90750050T patent/PT2184071T/pt unknown
- 2002-06-20 BR BRPI0210590-0 patent/BRPI0210590B8/pt not_active IP Right Cessation
- 2002-06-20 DE DE122010000041C patent/DE122010000041I1/de active Pending
- 2002-06-20 ES ES09075010.0T patent/ES2670219T3/es not_active Expired - Lifetime
- 2002-06-20 ES ES06075175T patent/ES2347458T3/es not_active Expired - Lifetime
- 2002-06-20 AT AT02755452T patent/ATE322287T1/de active
- 2002-06-20 PT PT101798064T patent/PT2277537E/pt unknown
- 2002-06-20 AT AT10007477T patent/ATE556718T1/de active
- 2002-06-20 EP EP10007477.2A patent/EP2263688B2/fr not_active Expired - Lifetime
- 2002-06-20 DK DK06075175.7T patent/DK1741442T3/da active
- 2002-06-20 EP EP06075175A patent/EP1741442B1/fr not_active Expired - Lifetime
- 2002-06-20 EP EP10180707A patent/EP2277539A3/fr not_active Ceased
- 2002-06-20 PT PT02755452T patent/PT1401489E/pt unknown
- 2002-06-20 PT PT101797975T patent/PT2277536T/pt unknown
- 2002-06-20 AU AU2002321716A patent/AU2002321716B2/en not_active Expired
- 2002-06-20 DE DE60237123T patent/DE60237123D1/de not_active Expired - Lifetime
- 2002-06-20 EP EP02755452.6A patent/EP1401489B2/fr not_active Expired - Lifetime
- 2002-06-20 MX MXPA03011462A patent/MXPA03011462A/es active IP Right Grant
- 2002-06-20 DK DK10179797.5T patent/DK2277536T3/en active
- 2002-06-20 ES ES10179806.4T patent/ES2539134T3/es not_active Expired - Lifetime
- 2002-06-20 DK DK09075006.8T patent/DK2189165T3/en active
- 2002-06-20 DE DE122010000040C patent/DE122010000040I1/de active Pending
- 2002-06-20 DK DK10007477.2T patent/DK2263688T4/da active
- 2002-06-20 CN CN200910128141.0A patent/CN101524535B/zh not_active Expired - Lifetime
- 2002-06-20 EP EP10179806.4A patent/EP2277537B1/fr not_active Expired - Lifetime
- 2002-06-20 DK DK02755452.6T patent/DK1401489T4/da active
- 2002-06-20 ES ES02755452T patent/ES2261705T5/es not_active Expired - Lifetime
- 2002-06-20 EP EP10179797.5A patent/EP2277536B1/fr not_active Expired - Lifetime
- 2002-06-20 ES ES09075009.2T patent/ES2670196T3/es not_active Expired - Lifetime
- 2002-06-20 CN CNA2009101281393A patent/CN101524533A/zh active Pending
- 2002-06-20 DE DE122011000003C patent/DE122011000003I1/de active Pending
- 2002-06-20 TR TR2018/08026T patent/TR201808026T4/tr unknown
- 2002-06-20 NZ NZ529881A patent/NZ529881A/xx not_active IP Right Cessation
- 2002-06-20 CA CA2730856A patent/CA2730856C/fr not_active Expired - Lifetime
- 2002-06-20 BR BR122019009186A patent/BR122019009186B8/pt not_active IP Right Cessation
- 2002-06-20 DK DK09075005.0T patent/DK2184071T3/en active
- 2002-06-20 DE DE60210456T patent/DE60210456T3/de not_active Expired - Lifetime
- 2002-06-20 ES ES10007477T patent/ES2387592T5/es not_active Expired - Lifetime
- 2002-06-20 PT PT10007477T patent/PT2263688E/pt unknown
- 2002-06-20 ES ES09075006.8T patent/ES2573259T3/es not_active Expired - Lifetime
2007
- 2007-07-24 AU AU2007203442A patent/AU2007203442B2/en not_active Expired
2009
- 2009-01-09 US US12/351,281 patent/US8889152B2/en not_active Expired - Lifetime
- 2009-01-14 US US12/353,409 patent/US8852606B2/en not_active Expired - Lifetime
- 2009-01-20 US US12/321,420 patent/US20090130147A1/en not_active Abandoned
- 2009-01-20 US US12/321,464 patent/US9358278B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/321,434 patent/US9782467B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/321,418 patent/US9782466B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/321,417 patent/US9452207B2/en not_active Expired - Fee Related
- 2009-02-26 JP JP2009044924A patent/JP5220658B2/ja not_active Expired - Lifetime
- 2009-02-26 JP JP2009044925A patent/JP5380111B2/ja not_active Expired - Lifetime
- 2009-03-11 RU RU2009108660/10A patent/RU2528066C2/ru active
2010
- 2010-09-13 NL NL300458C patent/NL300458I2/nl unknown
- 2010-09-13 BE BE2010C032C patent/BE2010C032I2/fr unknown
- 2010-09-13 BE BE2010C031C patent/BE2010C031I2/fr unknown
- 2010-09-13 FR FR10C0042C patent/FR10C0042I1/fr active Active
- 2010-09-13 FR FR10C0044C patent/FR10C0044I1/fr active Active
- 2010-09-13 NL NL300459C patent/NL300459I2/nl unknown
- 2010-09-13 NL NL300460C patent/NL300460I2/nl unknown
- 2010-09-13 BE BE2010C033C patent/BE2010C033I2/fr unknown
- 2010-09-13 FR FR10C0043C patent/FR10C0043I1/fr active Active
- 2010-09-14 LU LU91733C patent/LU91733I2/fr unknown
- 2010-09-14 LU LU91732C patent/LU91732I2/fr unknown
- 2010-09-14 LU LU91734C patent/LU91734I2/fr unknown
- 2010-10-11 CY CY20101100902T patent/CY1110820T1/el unknown
- 2010-11-19 AU AU2010246331A patent/AU2010246331B2/en not_active Expired
2011
- 2011-01-13 BE BE2011C001C patent/BE2011C001I2/fr unknown
- 2011-01-13 LU LU91778C patent/LU91778I2/fr unknown
- 2011-01-14 FR FR11C0001C patent/FR11C0001I2/fr active Active
- 2011-01-18 CY CY2011001C patent/CY2011001I1/el unknown
2012
- 2012-08-03 CY CY20121100693T patent/CY1113020T1/el unknown
- 2012-10-05 JP JP2012222942A patent/JP2013007057A/ja not_active Withdrawn
2016
- 2016-05-18 CY CY20161100432T patent/CY1117528T1/el unknown
- 2016-10-21 CY CY20161101065T patent/CY1118130T1/el unknown
- 2016-10-31 US US15/339,741 patent/US10716841B2/en not_active Expired - Fee Related
2018
- 2018-03-30 CY CY20181100356T patent/CY1120499T1/el unknown

Also Published As

Publication number	Publication date
BR122019009186B1 (pt)	2020-05-26
RU2004101284A (ru)	2005-06-27
EP2229954B1 (fr)	2018-03-21
AU2007203442B2 (en)	2010-08-26
CN101524533A (zh)	2009-09-09
NL300459I2 (fr)	2016-12-20
EP2277539A2 (fr)	2011-01-26
CY1118130T1 (el)	2017-06-28
DE60210456T2 (de)	2006-11-16
EP1401489B1 (fr)	2006-04-05
US20090181049A1 (en)	2009-07-16
EP2216044A1 (fr)	2010-08-11
DK1401489T4 (da)	2013-07-01
PT2184071T (pt)	2016-11-14
EP2216044B1 (fr)	2018-03-21
EP1741442B1 (fr)	2010-07-21
EP2277536A3 (fr)	2011-02-23
LU91733I2 (fr)	2011-03-14
BRPI0210590B8 (pt)	2021-05-25
US20050106181A1 (en)	2005-05-19
LU91733I9 (fr)	2019-01-07
RU2381814C2 (ru)	2010-02-20
US20090182128A1 (en)	2009-07-16
ES2539134T3 (es)	2015-06-26
WO2003007985A3 (fr)	2003-12-24
WO2003007985A2 (fr)	2003-01-30
PT1401489E (pt)	2006-08-31
LU91734I2 (fr)	2011-03-14
EP2277537A3 (fr)	2011-03-02
LU91778I2 (fr)	2011-03-14
CA2641585A1 (fr)	2003-01-30
FR10C0044I1 (fr)	2010-10-29
ES2387592T3 (es)	2012-09-26
MXPA03011462A (es)	2005-04-19
CN101524534B (zh)	2014-05-28
US9358278B2 (en)	2016-06-07
PT1741442E (pt)	2010-10-28
EP1401489B2 (fr)	2013-04-10
BR122019009186B8 (pt)	2021-07-27
CY1110820T1 (el)	2012-01-25
LU91732I9 (fr)	2019-01-07
US9782466B2 (en)	2017-10-10
AU2010246331B2 (en)	2012-11-08
CY1117528T1 (el)	2017-04-26
BE2010C031I2 (fr)	2021-07-19
US20090130140A1 (en)	2009-05-21
DE60210456T3 (de)	2013-09-05
US20090181053A1 (en)	2009-07-16
CY2011001I2 (el)	2012-01-25
US20090182129A1 (en)	2009-07-16
FR10C0043I1 (fr)	2010-10-29
LU91778I9 (fr)	2019-01-07
JP2004536859A (ja)	2004-12-09
NL300458I2 (fr)	2016-12-20
US20170043004A1 (en)	2017-02-16
US20090130147A1 (en)	2009-05-21
FR10C0042I1 (fr)	2010-10-29
CY1120499T1 (el)	2019-07-10
DE122011000003I1 (de)	2011-05-05
EP2184071B1 (fr)	2016-08-31
EP2277539A3 (fr)	2011-03-02
NZ544332A (en)	2006-10-27
DE122010000040I1 (de)	2010-12-16
CA2641585C (fr)	2011-02-08
US8889152B2 (en)	2014-11-18
FR11C0001I1 (fr)	2011-02-25
RU2528066C2 (ru)	2014-09-10
DK1741442T3 (da)	2010-08-30
BE2010C032I2 (fr)	2021-07-19
EP2184071A1 (fr)	2010-05-12
TR201808026T4 (tr)	2018-06-21
ES2603275T3 (es)	2017-02-24
BR0210590A (pt)	2004-11-09
FR11C0001I2 (fr)	2017-05-19
JP2009114210A (ja)	2009-05-28
AU2002321716B2 (en)	2007-04-26
EP2277536B1 (fr)	2018-01-31
AU2010246331A1 (en)	2010-12-09
JP5075317B2 (ja)	2012-11-21
ES2662015T3 (es)	2018-04-05
DK2277536T3 (en)	2018-02-26
DK1401489T3 (da)	2006-07-03
ATE474594T1 (de)	2010-08-15
EP2263688A1 (fr)	2010-12-22
US9452207B2 (en)	2016-09-27
BE2011C001I2 (fr)	2021-07-19
PT2263688E (pt)	2012-08-02
DK2189165T3 (en)	2016-06-13
DE122010000042I1 (de)	2010-12-16
LU91732I2 (fr)	2011-03-14
CN101524535A (zh)	2009-09-09
EP2263688B2 (fr)	2019-12-25
DK2184071T3 (en)	2016-11-07
EP2277537B1 (fr)	2015-03-25
ES2387592T5 (es)	2020-07-30
EP2229954A1 (fr)	2010-09-22
AU2007203442A1 (en)	2007-08-16
US20090117148A1 (en)	2009-05-07
CN101524535B (zh)	2015-12-16
NZ529881A (en)	2006-03-31
ES2261705T3 (es)	2006-11-16
JP5220658B2 (ja)	2013-06-26
EP2277537A2 (fr)	2011-01-26
EP2189165A1 (fr)	2010-05-26
EP1401489A2 (fr)	2004-03-31
DE60210456D1 (de)	2006-05-18
ES2261705T5 (es)	2013-07-22
JP5380111B2 (ja)	2014-01-08
JP2009114211A (ja)	2009-05-28
EP2277536A2 (fr)	2011-01-26
JP2013007057A (ja)	2013-01-10
TR201808055T4 (tr)	2018-06-21
NL300460I2 (fr)	2016-12-20
RU2009108660A (ru)	2010-09-20
US9782467B2 (en)	2017-10-10
CA2730856A1 (fr)	2003-01-30
CN101524534A (zh)	2009-09-09
DK2263688T3 (da)	2012-07-30
DK2263688T4 (da)	2020-03-02
CY1113020T1 (el)	2016-04-13
ES2670196T3 (es)	2018-05-29
EP2189165B1 (fr)	2016-03-09
US10716841B2 (en)	2020-07-21
US8852606B2 (en)	2014-10-07
PT2277536T (pt)	2018-03-21
GB0115176D0 (en)	2001-08-15
ATE556718T1 (de)	2012-05-15
US8753651B2 (en)	2014-06-17
EP1741442A2 (fr)	2007-01-10
LU91734I9 (fr)	2019-01-07
ES2347458T3 (es)	2010-10-29
DE122010000041I1 (de)	2010-12-16
CN100482273C (zh)	2009-04-29
CA2450203A1 (fr)	2003-01-30
EP2263688B1 (fr)	2012-05-09
CA2730856C (fr)	2015-07-28
PT2277537E (pt)	2015-06-30
ES2573259T3 (es)	2016-06-06
CY2011001I1 (el)	2012-01-25
CN1518456A (zh)	2004-08-04
DE60237123D1 (de)	2010-09-02
EP1741442A3 (fr)	2007-01-17
ATE322287T1 (de)	2006-04-15
BRPI0210590B1 (pt)	2019-10-01
ES2670219T3 (es)	2018-05-29
CA2450203C (fr)	2011-04-19

Publication	Publication Date	Title
NL300459I2 (fr)	2016-12-20
MXPA03008961A (es)	2004-02-12	Composicion de vacuna.
WO2003051392A3 (fr)	2003-11-13	Vaccin
MXPA03007915A (es)	2003-12-04	Vacuna.
AU2002322059A1 (en)	2002-12-23	Improved vaccination against anthrax
WO2000025814A3 (fr)	2000-07-27	Constituant pour un vaccin
AU2002342949A1 (en)	2003-06-19	Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other
AU2002315309A1 (en)	2002-11-05	Vaccine against tuberculosis
AU2002365113A1 (en)	2003-07-15	Enterococcal virulence factors
AU2002336375A1 (en)	2003-03-03	Improved conjugate vaccines
AU2002321781A1 (en)	2003-03-24	Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses